Ganglioside biosynthesis enzyme

Ganglioside biosynthesis enzymes represent a group of glycosyltransferases responsible for the sequential addition of sugar moieties to ceramide backbones to form complex gangliosides. This family includes key enzymes such as glucosylceramide synthase (UGCG), GM3 synthase (ST3GAL5), and GD3 synthase (ST8SIA1), which are localized primarily in the Golgi apparatus. These enzymes play critical roles in maintaining the structural integrity of cell membranes, particularly in the central nervous system where gangliosides are most abundant and involved in cell signaling and neural development. In therapeutic contexts, these enzymes are targeted primarily through substrate reduction therapy (SRT) to treat lysosomal storage diseases like Gaucher or Fabry disease by limiting the accumulation of toxic substrates. Additionally, specific enzymes like GD3 synthase are investigated in oncology, as certain gangliosides are overexpressed in tumors and contribute to cell proliferation and metastasis. While 'ganglioside biosynthesis enzyme' is a broad functional category rather than a single protein, it is a recognized focal point for drug development in metabolic and neurodegenerative disorders.

Other names

Glycosphingolipid glycosyltransferaseGanglioside synthaseSialyltransferaseGalactosyltransferase

Substrate reduction therapy (SRT) via inhibition of glucosylceramide synthase to decrease the production of downstream gangliosides.